




GlycoNex Inc.

2023 Investor Conference

Targeting the Sweets Spots in Antigens

GlycoNex Over The Years





Our Pipelines

			Indication	Lead development	Preclinical	Clinical P1	Clinical P2
Anti-Cancer	GNX102	First-in-class antibody	oncology				
	GNX201	Pro-antibody	oncology				
	GNX202	Pro-antibody	oncology				
	GNX203	Pro-antibody	oncology				
			Indication	Process development	Preclinical	Clinical P1	Clinical P3
Biosimilar	SPD8	Denosumab Biosimilar	Osteoporosis Oncology				
	SEA	Aflibercept Biosimilar	AMD Oncology				
Ab Bank	New Candidates	> 50 mAb, Potential candidates for anti-cancer treatment.					

From Lead Discovery to Clinical Phase

-The Science Behind Our Antibodies



Innovative drugs



Anti-glycan Antibody

GNX102

- A first-in-class antibody drug targeting a novel glycan antigen
- Targeting multiple cancers
- Phase 1 clinical trial (USA & TW)

GNX201

A new type antibody with lower toxicity and better specificity by combining our novel technology with ADC.

GNX202


A new type antibody with better specificity and higher efficacy

GNX203

A new type antibody with better specificity and higher efficacy

GNX102: Phase 1 clinical study

13 cancers



Sites:

US: 5 sites

TW: 2 sites

End in 2023



Effective
Biomarker




Target
Population




Increase in
Clinical Success

GNX201




Colon (normal)





GNX201: No/Weak binding

Colon (cancerous)



Activated GNX201: Strong binding



ADC

Antibody drug conjugate

Biosimilar SPD8



Osteoporosis & Oncology



Analytical Similarity

Highly similar to originators




Pre-clinical Similarity

Highly similar to originators



Clinical Similarity

May 2023 in Japan





Manufacture

Robust process

Co-development with Mitsubishi Gas Chemical

Denosumab : Prolia® and Xgeva® 年銷售額





Eylea® (aflibercept)

Bayer and Regeneron

2017 銷售: **\$58億美元**

2018 銷售: **\$65億美元**



2019 銷售: **\$74億美元**

2022 銷售: **\$94億美元**

Source: <https://www.creative-biolabs.com/blog/index.php/prediction-top10-best-selling-drugs/> <https://www.genengnews.com/a-lists/top-15-best-selling-drugs-of-2018/>

Antibody Bank

More than 50 anti-glycan antibodies



Cancer-associated glycan antigen

-Targeting multiple type cancers



Well defined specificity

-Extensive research data collection



Sequence available

-Expression vector ready



Manufacturable

-Serum-free, purified samples available

GMP-compliant Manufacturing Facility



Upstream

Equipped with 50L & 200L bioreactors



Downstream



Quality

Our Business Model



- Out-licensing / co-develop our assets
- Partnering for ADC development, bi-specific Ab development and cell therapy development
- Providing GlycoSH for Screening candidates of interest
- Antibody drug development service for client's leads from DNA to clinical stage